View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 24, 2016

Helix begins second cohort enrolment for Phase I US trial of lung cancer drug

Helix BioPharma has started patient enrolment in the second dosing cohort of its US-based Phase I trial (LDOS001) to evaluate its first immunoconjugate-based drug candidate, L-DOS47.

Helix BioPharma has started patient enrolment in the second dosing cohort of its US-based Phase I trial (LDOS001) to evaluate its first immunoconjugate-based drug candidate, L-DOS47.

L-DOS47 is being tested in combination with pemetrexed / carboplatin as a treatment for certain patients with non-small cell lung cancer (NSCLC).

US-based Helix is a biopharmaceutical firm that develops new drug candidates for the prevention and treatment of cancer.

The Safety Review Committee (SRC) recommended that the company start enroling a new patients, after reviewing safety data from the trial’s first dosing cohort.

Patients enroled in the second cohort will receive the next L-DOS47 dose level, which is 0.78 micrograms of L-DOS47 per kg of patient body weight.

L-DOS47 is being developed based on the company’s new DOS47 platform technology, which is designed to modify the microenvironmental conditions of, and eventually eliminate, cancer cells.

The Phase I LDOS001 trial is being carried out in the US at three centres: The University of Texas, M.D. Anderson Cancer Centre, Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center.

The trial’s primary objective is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed / carboplatin.

LDOS002 is an open-label Phase I / II trial being conducted in Poland to evaluate the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47.

The treatment is initially being tested as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb / IV NSCLC.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena